1.CeFe nanofibrous carbon nanozyme integrated with smartphone for the point-of-care testing of norfloxacin in water
Liu YUE ; Cai TAIMEI ; Chen SEN ; Wen TAO ; Peng HAILONG
Journal of Pharmaceutical Analysis 2024;14(10):1505-1513
The overuse of antibiotics has led to the severe contamination of water bodies,posing a considerable hazard to human health.Therefore,the development of an accurate and rapid point-of-care testing(POCT)platform for the quantitative detection of antibiotics is necessary.In this study,Cerium oxide(CeO2)and Ferrosoferric oxide(Fe3O4)nanoparticles were simultaneously encapsulated into N-doped nanofibrous carbon microspheres to form of a novel nanozyme(CeFe-NCMzyme)with a porous struc-ture,high surface area,and N-doped carbon material properties,leading to a considerable enhancement of the peroxidase(POD)-like activity compared with that of the CeO2 or Fe3O4 nanoparticles alone.The POD-like activity of CeFe-NCMzyme can be quenched using L-Cysteine(Cys)and subsequently restored by the addition of a quinolone antibiotic(norfloxacin,NOR).Therefore,CeFe-NCMzyme was used as a colorimetric sensor to detect NOR via an"On-Off"model of POD-like activity.The sensor possessed a wide linear range of 0.05-20.0 μM(R2=0.9910)with a detection limit of 35.70 nM.Furthermore,a smartphone-assisted POCT platform with CeFe-NCMzyme was fabricated for quantitative detection of NOR based on RGB analysis.With the use of the POCT platform,a linear range of 0.1-20.0 μM and a detection limit of 54.10 nM were obtained.The spiked recoveries in the water samples were ranged from 97.73%to 102.01%,and the sensor exhibited good accuracy and acceptable reliability.This study provides a portable POCT platform for the on-site and quantitative monitoring of quinolone antibiotics in real samples,particularly in resource-constrained settings.
2.Current GMP in China vs. the 2008 Version GMP in European Union
China Pharmacy 2005;0(22):-
OBJECTIVE:To promote the development of GMP in China.METHODS:Based on our practice in the EU GMP-certified pharmaceutical companies,the differences between current GMP in China and the 2008 version GMP in EU was compared in aspects of personnel,workshop and equipment,GMP documentation,production management,quality control,quality management and environment,etc.RESULTS & CONCLUSIONS:There are great differences between the current GMP in China and the 2008 version GMP in EU in terms of production management and GMP software,etc.In revising GMP,we should draw experiences from EU about their advanced management ideas.

Result Analysis
Print
Save
E-mail